Better Health, Brighter Future
Shire plc (LSE: SHP, NASDAQ: SHPGY), today announced the appointment of Frédéric Chereau as Senior Vice President and Franchise Lead, Angioedema, for its Human Genetic Therapies (HGT) business. In this role, Frédéric will oversee the development and execution of the global strategy for the angioedema franchise.He will report to Sylvie Grégoire, President of Shire HGT. Frédéricwill be based in Shire’s office in Lexington, Massachusetts.
“Frédéric brings a wealth of experience from top pharmaceutical and biotech companies to Shire HGT, and we know he will be an important asset as we continue to grow and develop our Angioedema Franchise,” said Sylvie Grégoire, President, Shire HGT. “With our recent strategic hires, we continue to strengthen our leadership team at HGT, and Frédéric will support our goal of helpingthose with rare diseases lead better lives.”
Frédéric was previously President and CEO of Pervasis Therapeutics, which was recently acquired by Shire Regenerative Medicine. Prior to Pervasis, he spent nine years with Genzyme Corporation where he held a number of positions of increasing responsibilityin Europe and the US, including Vice President and General Manager, leading the company’s global cardiovascular business unit. Frédéric began his career with Hemotech in France where he held various sales and marketing positions.
Frédéric is currently a Member of the Board of Directors of the French American Chamber of Commerce of New England and a Member of Strategic Advisory Board of the La Rochelle Business School.Fluent in both French and English, Frédéric holds a Bachelor’s Degree in Physics from the University of Paris, a Master’s Degree in Business Administration from La Rochelle Business School and an Executive MBA from INSEAD.
For further information please contact:
| Media | ||
| Jessica Cotrone | [email protected] | +781 482 9538 |
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Through our deep understanding of patients’ needs, we develop and provide healthcare in the areas of:
as well as other symptomatic conditions treated by specialist physicians.
We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.